<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10529442</article-id><article-id pub-id-type="pmcid-ver">PMC10529442.319</article-id><article-id pub-id-type="pmcaid">10529442</article-id><article-id pub-id-type="pmcaiid">10529442</article-id><article-id pub-id-type="manuscript-id">NIHMS1916657</article-id><article-id pub-id-type="pmid">37413960</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2023.110875</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1916657</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1916657</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hammerslag</surname><given-names initials="L">Lindsey</given-names></name><degrees>PhD</degrees><aff id="A1">Division of Biomedical Informatics, College of Medicine, University of Kentucky</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Talbert</surname><given-names initials="J">Jeffery</given-names></name><degrees>PhD</degrees><aff id="A2">Institute for Biomedical Informatics, College of Medicine, University of Kentucky</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donohue</surname><given-names initials="JM">Julie M.</given-names></name><degrees>PhD</degrees><aff id="A3">Health Policy and Management, University of Pittsburgh School of Public Health</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharbaugh</surname><given-names initials="M">Michael</given-names></name><degrees>MPH</degrees><aff id="A4">Department of Health Policy and Management, University of Pittsburgh School of Public Health</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahrens</surname><given-names initials="K">Katherine</given-names></name><degrees>PhD, MPH</degrees><aff id="A5">University of Southern Maine, Muskie School of Public Service</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Allen</surname><given-names initials="L">Lindsay</given-names></name><degrees>PhD, MA</degrees><aff id="A6">Feinberg School of Medicine, Northwestern University</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Austin</surname><given-names initials="AE">Anna E.</given-names></name><degrees>PhD</degrees><aff id="A7">Gillings School of Global Public Health and Injury Prevention Research Center, University of North Carolina at Chapel Hill</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon</surname><given-names initials="AJ">Adam J.</given-names></name><degrees>MD, MPH</degrees><aff id="A8">Program for Addiction Research, Clinical Care, Knowledge, and Advocacy, Department of Internal Medicine, University of Utah School of Medicine and VA Salt Lake City Health Care System</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jarlenski</surname><given-names initials="M">Marian</given-names></name><degrees>PhD, MPH</degrees><aff id="A9">Department of Health Policy and Management, University of Pittsburgh School of Public Health</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="JY">Joo Yeon</given-names></name><degrees>MS</degrees><aff id="A10">Department of Health Policy and Management, University of Pittsburgh School of Public Health</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mohamoud</surname><given-names initials="S">Shamis</given-names></name><degrees>MA</degrees><aff id="A11">The Hilltop Institute, University of Maryland Baltimore County</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="L">Lu</given-names></name><degrees>PhD</degrees><aff id="A12">Department of Biostatistics, University of Pittsburgh School of Public Health</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burns</surname><given-names initials="M">Marguerite</given-names></name><degrees>PhD</degrees><aff id="A13">Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin</aff></contrib></contrib-group><author-notes><fn fn-type="other" id="FN1"><p id="P1">Writing committee for MODRN*</p></fn><fn fn-type="con" id="FN2"><p id="P2"><bold>Contributors:</bold> LH, JT and MB served as the leads for experimental design and manuscript preparation and contributed to all aspects of the study. JD, KA, LA, AEA, AJG, MJ, and SM were involved in the design and execution of the study plan and provided critical feedback on the prepared manuscript. MS, JYK and LT developed the analytic code and provided leadership for the design and execution of data collection and statistical analyses.</p></fn><corresp id="CR1"><label>*</label>Corresponding author</corresp><fn fn-type="COI-statement" id="FN4"><p id="P30"><bold>Conflict of Interest:</bold> No conflict declared.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>24</day><month>6</month><year>2023</year></pub-date><volume>250</volume><issue-id pub-id-type="pmc-issue-id">446078</issue-id><fpage>110875</fpage><lpage>110875</lpage><pub-history><event event-type="nihms-submitted"><date><day>15</day><month>07</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-01 00:25:27.713"><day>01</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1916657.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background</title><p id="P3">Treatment guidelines recommend regular urine drug testing (UDT) for persons initiating buprenorphine for opioid use disorder (OUD). However, little is known about UDT utilization. We describe state variation in UDT utilization and examine demographic, health, and health care utilization factors associated with UDT in Medicaid.</p></sec><sec id="S2"><title>Methods</title><p id="P4">We used Medicaid claims and enrollment data from persons initiating buprenorphine treatment for OUD during 2016&#8211;2019 in 9 states (DE, KY, MD, ME, MI, NC, PA, WI, WV). The main outcome was at least 1 UDT within 180 days of buprenorphine initiation, the secondary outcome was at least 3. Logistic regression models included demographics, pre-initiation comorbidities, and health service use. State estimates were pooled using metaanalysis.</p></sec><sec id="S3"><title>Results</title><p id="P5">The study cohort included 162,437 Medicaid enrollees initiating buprenorphine. The percent receiving &#8805;1 UDT varied from 62.1% to 89.8% by state. In the pooled analysis, enrollees with pre-initiation UDT had much higher odds of &#8805;1 UDT after initiation (aOR=3.83, 3.09&#8211;4.73); odds were also higher for enrollees with HIV, HCV, and/or HBV infection (aOR=1.25, 1.05&#8211;1.48) or who initiated in later years (2018 v 2016: aOR=1.39, 1.03&#8211;1.89; 2019 v 2016: aOR=1.67, 1.24&#8211;2.25). The odds of having &#8805;3 UDT were lower with pre-initiation opioid overdose (aOR=0.79, 0.64&#8211;0.96) and higher with pre-initiation UDT (aOR=2.63, 2.13&#8211;3.25) or OUD care (aOR=1.35, 1.04&#8211;1.74). The direction of associations with demographics varied by state.</p></sec><sec id="S4"><title>Conclusions</title><p id="P6">Rates of UDT increased over time and there was variability among states in UDT rates and demographic predictors of UDT. Pre-initiation conditions, UDT, and OUD care were associated with UDT.</p></sec></abstract><kwd-group><kwd>drug testing</kwd><kwd>urinalysis</kwd><kwd>buprenorphine</kwd><kwd>Medicaid</kwd><kwd>opioid use disorder</kwd><kwd>overdose</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>